AMGN

435.6400.15%
JE

James E. Bradner

Founder

Dr. James E. Bradner, also known as Jay, M.D., is Executive Vice President of Research and Development of Amgen Inc. since December 18, 2023, is EVP of Artificial Intelligence and Data since June 1, 2026 and served as its Chief Scientific Officer until December 16, 2024. He had been President of Novartis Institutes for BioMedical Research, Inc. at Novartis AG since March 1, 2016 until October 31, 2022. Dr. Bradner is Member of Strategic Advisory Board at Longwood Fund since November 2022. Dr. Bradner is the Scientific Founder of Acetylon Pharmaceuticals, Inc. Dr. Bradner was the Founder of C4 Therapeutics, Inc. He is a Scientific Founder of Acetylon Pharmaceuticals, Inc., TetraLogic Research and Development Corporation and Tensha Therapeutics, Inc. He was physician at Department of Medical Oncology, Dana-Farber Cancer Institute, US since 2005 until 2015. He serves as Staff Physician at Dana Farber Cancer Institute. He serves as Physician-Scientist, Chemical Biology Group, Broad Institute; Associate Physician, Brigham and Women’s Hospital; and Instructor of Medicine, Harvard Medical School. He leads a chemical biology group at the Broad Institute investigating cellular function of histone deacetylases and the role of autophagy in hematologic malignancies. His group applies forward and reverse chemical genetic platforms, high-content screening and small-molecule microarrays for ligands modulating autophagy. Dr. Bradner is Associate Director of the Center for the Science of Therapeutics (CSofT) at the Broad Institute where he has worked since 2004. He served as an Assistant Professor of Medicine at Harvard Medical School since 2010 until 2014. He was an Associate Professor of department of Medicine at Harvard Medical School since 2014 until 2016. He is the Founder of Syros Pharmaceuticals, Inc. He serves as a Director of Tensha Therapeutics, Inc. He serves as a Director AT TetraLogic Research and Development Corporation. His research and leadership have contributed to numerous development programs, multiple investigational new drug applications and positive proof-of-concept studies in clinical investigation. He serves as a Member of Scientific Advisory Board at Acetylon Pharmaceuticals, Inc. He served as a Member of the Supervisory Board at Qiagen NV since June 2015 until December 31, 2015. He is a Co-Founder of five biotechnology companies and Co-author of more than 250 scientific publications and 50 US patent applications. He serves as a Science advisor for the Abdul Latif Jameel Clinic for Machine Learning in Health, Massachusetts Institute of Technology, US and for Brigham and Women’s Hospital, US and Chairman, Genomics Institute of the Novartis Research Foundation, US. He served as a Director and Member of Scientific Advisory Board at Syros Pharmaceuticals since April 2013 until October 2015. He served as a Member of Scientific Advisory Board at Agios Pharmaceuticals, Inc., since November 24, 2008. He has received many honorific awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013. From 2005 through 2015, Dr. Bradner served on the research faculty of Harvard Medical School and He completed his residency in medicine at Brigham and Women’s Hospital, his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute and his postdoctoral training in chemistry and chemical biology at Harvard University. He is attending physician in stem cell transplantation within the Department of Medical Oncology at the Dana-Farber Cancer Institute. Dr. Bradner received Bachelor’s degree in biochemistry, Harvard University, US, his M.D. from University of Chicago Pritzker School of Medicine, US and Postdoctoral training in chemistry and chemical biology, Harvard University, U.S.

Positions